| Literature DB >> 31701687 |
Eun Jin Kim1, Kyoung Hwa Ha2,3, Dae Jung Kim2,3, Young Hwa Choi4.
Abstract
BACKGROUND: Several studies have shown that people with diabetes are vulnerable to infection. This study compared the risk of infection-related hospitalizations, intensive care unit (ICU) admission, and deaths between the person with diabetes and the general population in South Korea.Entities:
Keywords: Diabetes mellitus; Hospitalization; Infection
Year: 2019 PMID: 31701687 PMCID: PMC6943267 DOI: 10.4093/dmj.2019.0071
Source DB: PubMed Journal: Diabetes Metab J ISSN: 2233-6079 Impact factor: 5.376
Fig. 1Flow chart showing the process for selection of members of the study cohort.
Baseline characteristics among diabetics and non-diabetic controls
| Characteristic | DM ( | Non-DM ( | |
|---|---|---|---|
| Age, yr | 58.2±13.3 | 58.2±13.3 | 0.740 |
| Female sex | 33,484 (50.4) | 66,968 (50.4) | 1.000 |
| Household incomea | <0.001 | ||
| Upper 30% | 15,524 (30.1) | 28,730 (26.2) | |
| Mid 40% | 22,746 (44.2) | 48,942 (44.6) | |
| Lower 30% | 13,216 (25.7) | 32,037 (29.2) | |
| Time since diagnosis, yr | |||
| 0–3 | 42,085 (63.4) | ||
| ≥4 | 24,341 (36.6) | ||
| Drugs | |||
| Use of glucose-lowering drugs | |||
| Metformin | 26,490 (39.9) | ||
| Sulfonylureas | 40,535 (61.0) | ||
| Thiazolidinediones | 7,215 (10.9) | ||
| Insulin | 12,648 (19.0) | ||
| Other GLDs | 16,949 (25.5) | ||
| Anthihypertensive drugs | 45,243 (68.1) | 54,200 (40.8) | <0.001 |
| ACEi/ARB | 19,358 (29.1) | 15,746 (11.8) | <0.001 |
| Dihydropyridines | 31,307 (47.1) | 36,412 (27.4) | <0.001 |
| Diuretics | 25,796 (38.8) | 32,708 (24.6) | <0.001 |
| β-Blockers | 23,178 (34.9) | 28,886 (21.7) | <0.001 |
| Statin | 21,103 (31.8) | 13,234 (10.0) | <0.001 |
| Aspirin | 26,715 (40.2) | 27,396 (20.6) | <0.001 |
| Comorbidity | |||
| Hypertension | 47,933 (72.2) | 56,564 (42.6) | <0.001 |
| Dyslipidemia | 41,487 (62.5) | 30,291 (22.8) | <0.001 |
| Cardiovascular disease | 5,469 (8.2) | 4,276 (3.2) | <0.001 |
| Myocardial infarction | 1,479 (2.2) | 990 (0.7) | <0.001 |
| Heart failure | 1,135 (1.7) | 667 (0.5) | <0.001 |
| Stroke | 3,338 (5.0) | 3,202 (2.4) | <0.001 |
| PAD | 628 (0.9) | 213 (0.2) | <0.001 |
| Chronic kidney disease | 828 (1.2) | 213 (0.2) | <0.001 |
Values are presented as mean±standard deviation or number (%).
DM, diabetes mellitus; GLD, glucose-lowering drug; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; PAD, peripheral artery disease.
an=161,195.
Incidence rates of infection-related hospitalizations among diabetics and non-diabetic controls
| Type of infection | People with diabetes | Control | Diabetes vs. Control | |||
|---|---|---|---|---|---|---|
| No. of events | Event rate (per 1,000 yr) | No. of events | Event rate (per 1,000 yr) | IRR (95% CI) | Adjusted IRR (95% CI) | |
| Gastrointestinal | 8,005 | 14.66 | 5,448 | 5.42 | 2.71 (2.61–2.80) | 2.04 (1.95–2.13) |
| Mycoses | ||||||
| Candidiasis | 2,709 | 4.96 | 2,960 | 2.94 | 1.68 (1.60–1.77) | 1.36 (1.28–1.46) |
| Other fungal | 1,392 | 2.55 | 1,220 | 1.21 | 2.10 (1.94–2.27) | 1.17 (1.06–1.29) |
| Infective otitis externa | 289 | 0.53 | 803 | 0.80 | 0.66 (0.58–0.76) | 0.76 (0.64–0.90) |
| Otitis media & mastoiditis | 772 | 1.41 | 637 | 0.63 | 2.23 (2.01–2.48) | 2.29 (1.98–2.63) |
| Respiratory | 19,578 | 35.84 | 19,478 | 19.37 | 1.85 (1.81–1.89) | 1.76 (1.72–1.81) |
| Pneumonia | 13,743 | 25.16 | 12,195 | 12.13 | 2.07 (2.02–2.13) | 1.57 (1.52–1.62) |
| Hepatic abscess | 310 | 0.57 | 325 | 0.32 | 1.76 (1.50–2.05) | 10.17 (7.04–14.67) |
| Cholecystitis | 2,695 | 4.93 | 3,314 | 3.30 | 1.50 (1.42–1.57) | 1.33 (1.25–1.41) |
| Skin | ||||||
| Cellulitis | 2,536 | 4.64 | 2,878 | 2.86 | 1.62 (1.54–1.71) | 1.52 (1.42–1.63) |
| Other | 2,123 | 3.89 | 1,548 | 1.54 | 2.52 (2.36–2.70) | 3.52 (3.20–3.88) |
| Bone and joint infections | 1,114 | 2.04 | 1,414 | 1.41 | 1.45 (1.34–1.57) | 1.74 (1.57–1.94) |
| Myositis, synovitis and tenosynovitis | 372 | 0.68 | 354 | 0.35 | 1.93 (1.67–2.24) | 2.84 (2.24–3.61) |
| Urinary tract infection | 13,172 | 24.12 | 10,837 | 10.78 | 2.24 (2.18–2.30) | 1.83 (1.77–1.89) |
| Upper | 3,013 | 5.52 | 2,315 | 2.30 | 2.40 (2.27–2.53) | 1.78 (1.66–1.91) |
| Lower | 10,159 | 18.60 | 8,522 | 8.47 | 2.19 (2.13–2.26) | 1.85 (1.78–1.92) |
| CNS infection | 388 | 0.71 | 112 | 0.11 | 6.38 (5.17–7.87) | 8.72 (6.64–11.45) |
| Sepsis | 3,438 | 6.29 | 3,062 | 3.04 | 2.07 (1.97–2.17) | 2.21 (2.07–2.36) |
Adjusted for household income, hypertension, dyslipidemia, cardiovascular disease, and chronic kidney disease.
IRR, incidence rate ratio; CI, confidence interval; CNS, central nervous system.
Fig. 2Adjusted incidence rate ratios (IRRs) of infection-related hospitalizations in diabetes and matched non-diabetes controls, stratified by age, sex, comorbidities, and the use of insulin. The IRRs were estimated using Poisson models. CI, confidence interval.
Incidence rates of intensive care unit admissions and deaths among diabetics and non-diabetic controls
| Type of infection | People with diabetes | Control | Diabetes vs. Control | |||
|---|---|---|---|---|---|---|
| No. of events | Event rate (per 1,000 yr) | No. of events | Event rate (per 1,000 yr) | IRR (95% CI) | Adjusted IRR (95% CI) | |
| Gastrointestinal | 876 | 1.60 | 777 | 0.77 | 2.08 (1.88–2.29) | 2.06 (1.81–2.35) |
| Mycoses | ||||||
| Candidiasis | 254 | 0.47 | 583 | 0.58 | 0.80 (0.69–0.93) | 0.63 (0.53–0.74) |
| Other fungal | 342 | 0.63 | 490 | 0.49 | 1.28 (1.12–1.47) | 0.43 (0.37–0.50) |
| Infective otitis externa | 23 | 0.04 | 0 | 0.00 | ||
| Otitis media & mastoiditis | 48 | 0.09 | 42 | 0.04 | 2.10 (1.39–3.18) | 1.65 (0.96–2.84) |
| Respiratory | 1,483 | 2.72 | 863 | 0.86 | 3.16 (2.91–3.44) | 2.94 (2.64–3.29) |
| Pneumonia | 3,603 | 6.60 | 3,991 | 3.97 | 1.66 (1.59–1.74) | 0.98 (0.93–1.04) |
| Hepatic abscess | 50 | 0.09 | 0 | 0.00 | ||
| Cholecystitis | 386 | 0.71 | 509 | 0.51 | 1.40 (1.22–1.59) | 1.09 (0.93–1.27) |
| Skin | ||||||
| Cellulitis | 136 | 0.25 | 495 | 0.49 | 0.51 (0.42–0.61) | 0.46 (0.36–0.59) |
| Other | 214 | 0.39 | 56 | 0.06 | 7.04 (5.24–9.44) | 11.75 (7.32–18.86) |
| Bone and joint infections | 119 | 0.22 | 35 | 0.03 | 6.26 (4.29–9.13) | 4.78 (3.09–7.39) |
| Myositis, synovitis and tenosynovitis | 37 | 0.07 | 29 | 0.03 | 2.35 (1.44–3.82) | 1.43 (0.81–2.54) |
| Urinary tract infection | 1,850 | 3.39 | 2,126 | 2.11 | 1.60 (1.50–1.70) | 1.01 (0.94–1.09) |
| Upper | 292 | 0.53 | 100 | 0.10 | 5.38 (4.28–6.75) | 2.74 (2.11–3.56) |
| Lower | 1,558 | 2.85 | 2,026 | 2.01 | 1.42 (1.32–1.51) | 0.91 (0.84–0.99) |
| CNS infection | 137 | 0.25 | 35 | 0.03 | 7.21 (4.97–10.45) | 5.25 (3.53–7.79) |
| Sepsis | 1,359 | 2.49 | 777 | 0.77 | 3.22 (2.95–3.52) | 3.49 (3.05–3.92) |
Adjusted for household income, hypertension, dyslipidemia, cardiovascular disease, and chronic kidney disease.
IRR, incidence rate ratio; CI, confidence interval; CNS, central nervous system.